However, HER2-amplified tumours exhibit sensitivity to anti-HER2 therapies, such as trastuzumab (a monoclonal HER2 antibody) or lapatinib (a small molecule HER2 inhibitor) [46,95]. The gene discussed is ERBB2; the disease is neoplasm.